Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21880994rdf:typepubmed:Citationlld:pubmed
pubmed-article:21880994lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:21880994lifeskim:mentionsumls-concept:C1516985lld:lifeskim
pubmed-article:21880994lifeskim:mentionsumls-concept:C1513884lld:lifeskim
pubmed-article:21880994lifeskim:mentionsumls-concept:C0017636lld:lifeskim
pubmed-article:21880994lifeskim:mentionsumls-concept:C0042291lld:lifeskim
pubmed-article:21880994lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:21880994lifeskim:mentionsumls-concept:C0076080lld:lifeskim
pubmed-article:21880994lifeskim:mentionsumls-concept:C0439590lld:lifeskim
pubmed-article:21880994pubmed:issue12lld:pubmed
pubmed-article:21880994pubmed:dateCreated2011-9-20lld:pubmed
pubmed-article:21880994pubmed:abstractTextThis analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma.lld:pubmed
pubmed-article:21880994pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880994pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880994pubmed:languageenglld:pubmed
pubmed-article:21880994pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880994pubmed:citationSubsetAIMlld:pubmed
pubmed-article:21880994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880994pubmed:statusMEDLINElld:pubmed
pubmed-article:21880994pubmed:monthSeplld:pubmed
pubmed-article:21880994pubmed:issn1526-632Xlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:WellerMMlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:CairncrossJ...lld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:MasonWWlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:VechtC JCJlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:BogdahnUUlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:LacombeDDlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:MacdonaldD...lld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:van den...lld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:BelangerKKlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:StuppRRlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:ForsythPPlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:BrandesA AAAlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:GorliaTTlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:RossettiA OAOlld:pubmed
pubmed-article:21880994pubmed:authorpubmed-author:MirimanoffR-O...lld:pubmed
pubmed-article:21880994pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21880994pubmed:day20lld:pubmed
pubmed-article:21880994pubmed:volume77lld:pubmed
pubmed-article:21880994pubmed:ownerNLMlld:pubmed
pubmed-article:21880994pubmed:authorsCompleteYlld:pubmed
pubmed-article:21880994pubmed:pagination1156-64lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:meshHeadingpubmed-meshheading:21880994...lld:pubmed
pubmed-article:21880994pubmed:year2011lld:pubmed
pubmed-article:21880994pubmed:articleTitleProlonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.lld:pubmed
pubmed-article:21880994pubmed:affiliationDepartment of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, Switzerland. michael.weller@usz.chlld:pubmed
pubmed-article:21880994pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21880994pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:21880994pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:21880994pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed